Shares of Sartorius (OTCPK:SARTF) spiked in European trading on Wednesday after the German life sciences company recorded a ...

Monitoring blood levels of DNA fragments shed by dying tumor cells may accurately predict skin cancer recurrence, a new study shows.

Performance in the first half of the quarter was impacted by a cluster of companies with over 10% stock price moves. Read ...

RBC Capital lowered the firm’s price target on Bio-Rad (BIO) to $409 from $430 and keeps an Outperform rating on the shares as part of a ...

Strengthen Your Lab's Quality Control System Introduction Choosing the right quality control (QC) system for your laboratory ...

Bio-Rad Laboratories, Inc.’s BIO Clinical Diagnostics business is back to its usual growth trajectory post-pandemic while maintaining a strong market position worldwide for key platforms. The ...

RBC Capital analyst Conor McNamara maintained a Buy rating on Bio-Rad Laboratories (BIO – Research Report) on April 1 and set a price target of ...

Read Our Latest Stock Analysis on BIO Bio-Rad Laboratories Stock Performance NYSE BIO opened at $244.29 on Tuesday. Bio-Rad Laboratories, Inc. has a 52-week low of $235.84 and a 52-week high of ...

Bio-Techne Corporation TECH recently opened a new Customer Experience Centre in Düsseldorf, Germany, to serve customers across the Europe, Middle East and Africa (“EMEA”) region. The facility ...

Sartorius faces uncertainty with leadership changes and high debt levels. Read why DCF valuation models suggest SARTF stock may be overvalued.

Bio-Rad Laboratories, Inc manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates ...

WASHINGTON (March 26, 2025) -- Today, the Biotechnology Innovation Organization (BIO) released results from a membership survey that underscores the significant, global integration of the biomedical ...